spacer
spacer

PDBsum entry 4ews

Go to PDB code: 
protein ligands metals links
Lipid transport/inhibitor PDB id
4ews
Jmol PyMol
Contents
Protein chain
472 a.a.
Ligands
2OB ×2
DLP
PGE ×2
0RP
NAG-NAG-MAN-FUC
Metals
_CL
Waters ×81
PDB id:
4ews
Name: Lipid transport/inhibitor
Title: Crystal structure of cholesteryl ester transfer protein in c with inhibitors
Structure: Cetp. Chain: a. Engineered: yes
Source: Homo sapiens. Organism_taxid: 9606. Expressed in: cricetulus griseus. Expression_system_taxid: 10029. Expression_system_cell_line: dg44
Resolution:
2.59Å     R-factor:   0.215     R-free:   0.259
Authors: S.Liu,X.Qiu
Key ref: S.Liu et al. (2012). Crystal structures of cholesteryl ester transfer protein in complex with inhibitors. J Biol Chem, 287, 37321-37329. PubMed id: 22961980 DOI: 10.1074/jbc.M112.380063
Date:
27-Apr-12     Release date:   05-Sep-12    
PROCHECK
Go to PROCHECK summary
 Headers
 References

Protein chain
Pfam   ArchSchema ?
P11597  (CETP_HUMAN) -  Cholesteryl ester transfer protein
Seq:
Struc:
493 a.a.
472 a.a.*
Key:    PfamA domain  Secondary structure  CATH domain
* PDB and UniProt seqs differ at 5 residue positions (black crosses)

 Gene Ontology (GO) functional annotation 
  GO annot!
  Cellular component     extracellular region   5 terms 
  Biological process     transport   22 terms 
  Biochemical function     lipid binding     7 terms  

 

 
DOI no: 10.1074/jbc.M112.380063 J Biol Chem 287:37321-37329 (2012)
PubMed id: 22961980  
 
 
Crystal structures of cholesteryl ester transfer protein in complex with inhibitors.
S.Liu, A.Mistry, J.M.Reynolds, D.B.Lloyd, M.C.Griffor, D.A.Perry, R.B.Ruggeri, R.W.Clark, X.Qiu.
 
  ABSTRACT  
 
Human plasma cholesteryl ester transfer protein (CETP) transports cholesteryl ester from the antiatherogenic high-density lipoproteins (HDL) to the proatherogenic low-density and very low-density lipoproteins (LDL and VLDL). Inhibition of CETP has been shown to raise human plasma HDL cholesterol (HDL-C) levels and is potentially a novel approach for the prevention of cardiovascular diseases. Here, we report the crystal structures of CETP in complex with torcetrapib, a CETP inhibitor that has been tested in phase 3 clinical trials, and compound 2, an analog from a structurally distinct inhibitor series. In both crystal structures, the inhibitors are buried deeply within the protein, shifting the bound cholesteryl ester in the N-terminal pocket of the long hydrophobic tunnel and displacing the phospholipid from that pocket. The lipids in the C-terminal pocket of the hydrophobic tunnel remain unchanged. The inhibitors are positioned near the narrowing neck of the hydrophobic tunnel of CETP and thus block the connection between the N- and C-terminal pockets. These structures illuminate the unusual inhibition mechanism of these compounds and support the tunnel mechanism for neutral lipid transfer by CETP. These highly lipophilic inhibitors bind mainly through extensive hydrophobic interactions with the protein and the shifted cholesteryl ester molecule. However, polar residues, such as Ser-230 and His-232, are also found in the inhibitor binding site. An enhanced understanding of the inhibitor binding site may provide opportunities to design novel CETP inhibitors possessing more drug-like physical properties, distinct modes of action, or alternative pharmacological profiles.
 

 

spacer

spacer